Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is currently conducting a Phase 2 study titled A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma. The primary goal of this study is to evaluate the effectiveness of rocatinlimab in reducing asthma exacerbations, a significant concern for individuals with moderate-to-severe asthma.
The study is testing the drug rocatinlimab, administered via subcutaneous injection, to determine its efficacy and safety in comparison to a placebo. Rocatinlimab is designed to potentially reduce the frequency and severity of asthma attacks.
This interventional study employs a randomized, parallel assignment model with double masking to ensure unbiased results. The primary purpose is treatment-focused, aiming to provide a new therapeutic option for asthma patients.
The study began on May 24, 2024, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on August 20, 2025, indicating ongoing recruitment and progress.
For investors, this study could influence Amgen’s stock performance positively if rocatinlimab proves effective, potentially positioning the company as a leader in asthma treatment. This could also impact competitors in the respiratory treatment market.
The study is currently recruiting, with further details available on the ClinicalTrials portal.